Eculizumab
(Redirected from Soliris)
Eculizumab is a monoclonal antibody that is used in the treatment of various autoimmune diseases. It is marketed under the trade name Soliris by Alexion Pharmaceuticals.
Mechanism of Action[edit | edit source]
Eculizumab works by inhibiting the complement system, a part of the immune system that enhances the ability of antibodies and phagocytic cells to clear microbes and damaged cells from an organism. It does this by binding to the complement protein C5, preventing it from splitting into C5a and C5b. This inhibits the inflammatory response and the formation of the membrane attack complex, which is responsible for cell lysis.
Uses[edit | edit source]
Eculizumab is used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare, life-threatening disease of the blood characterized by hemolysis, thrombosis, and peripheral cytopenia. It is also used in the treatment of atypical hemolytic uremic syndrome (aHUS), another rare disease that causes abnormal blood clots to form in small blood vessels in the kidneys. More recently, it has been approved for use in treating neuromyelitis optica spectrum disorder (NMOSD), a rare neurological condition.
Side Effects[edit | edit source]
Common side effects of eculizumab include headache, nausea, anemia, and fatigue. Serious side effects can include life-threatening infections, such as meningococcal infections, due to the drug's effect on the immune system.
History[edit | edit source]
Eculizumab was first approved by the Food and Drug Administration (FDA) in 2007 for the treatment of PNH. It was the first drug approved for this condition. In 2011, it was approved for the treatment of aHUS. In 2019, it was approved for the treatment of NMOSD.
See Also[edit | edit source]
- Monoclonal antibodies
- Autoimmune diseases
- Paroxysmal nocturnal hemoglobinuria
- Atypical hemolytic uremic syndrome
- Neuromyelitis optica spectrum disorder
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
